Patents by Inventor Leonid Beigelman

Leonid Beigelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210277046
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 9, 2021
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J.F. Thuring
  • METHODS AND COMPOSITIONS FOR TARGETING PD-L1
    Publication number: 20210269797
    Abstract: The present disclosure relates to antisense oligonucleotides (ASOs) directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The ASO can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of ASOs and uses of or methods of using the ASOs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Inventors: Leonid Beigelman, Megan Elizabeth Fitzgerald, Saul Martinez Montero, Aneerban Bhattacharya
  • METHODS OF REDUCING VIRUS MOLECULE LEVELS
    Publication number: 20210230591
    Abstract: Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication. A pharmaceutical composition can include such an oligonucleotide inhibitor in an amount effective for treating an infection, such as a hepatitis B infection or a respiratory virus infection, such as a coronavirus infection.
    Type: Application
    Filed: November 6, 2020
    Publication date: July 29, 2021
    Inventors: Chia-Cheng Kao, Lawrence M. Blatt, Leonid Beigelman
  • OLIGONUCLEOTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20210196831
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: July 1, 2021
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Theodore YUN
  • S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
    Publication number: 20210189392
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 24, 2021
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong, Megan Elizabeth Fitzgerald
  • AZA-PYRIDONE COMPOUNDS AND USES THEREOF
    Publication number: 20210186969
    Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 24, 2021
    Applicant: Janssen BioPharma, Inc.
    Inventors: Robert Than HENDRICKS, Leonid BEIGELMAN, David Bernard SMITH, Antitsa Dimitrova STOYCHEVA
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20210179656
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Applicant: Janssen BioPharma, Inc.
    Inventors: Leonid BEIGELMAN, Guangyi WANG, David Bernard SMITH, Jerome DEVAL, Marija PRHAVC
  • Bicyclic sulfonamides
    Patent number: 11033556
    Abstract: Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 15, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, David Bernard Smith
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 11021509
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: June 1, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Jerome Deval, Marija Prhavc
  • Antiviral compounds
    Patent number: 11021444
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Cyclic dinucleotides as sting agonists
    Patent number: 11021511
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II) wherein R1H, R1K, R1J, and R2L are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan
  • Compounds for the treatment of paramyxovirus viral infections
    Patent number: 11014935
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20210139523
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 13, 2021
    Applicant: Janssen BioPharma, Inc.
    Inventors: Leonid BEIGELMAN, Guangyi WANG, David Bernard SMITH
  • Aza-pyridone compounds and uses thereof
    Patent number: 10980805
    Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: April 20, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Robert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20210106604
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 15, 2021
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
    Publication number: 20210095284
    Abstract: Oligonucleotides comprising modifications at the 2 and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: March 13, 2019
    Publication date: April 1, 2021
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE
    Publication number: 20210040483
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: October 5, 2020
    Publication date: February 11, 2021
    Applicant: Janssen Biopharma, Inc.
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL
  • Oligonucleotide constructs and uses thereof
    Patent number: 10905767
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 2, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Theodore Yun
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210009630
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2, X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 14, 2021
    Inventors: Leonid BEIGELMAN, Gilles BIGNAN, Peter J. CONNOLLY, James Patrick EDWARDS, Stuart EMANUEL, Sylvia LAQUERRE, Mark RICHTER, Wim Gert Griet SCHEPENS, Santhosh Kumar THATIKONDA, Johannes Wilhelmus John Fitzgerald THURING, Marcel VIELLEVOYE, Guangyi WANG, Minghong ZHONG
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 10889815
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: January 12, 2021
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese